Brief: Ocugen Announces Initiation Of Enrollment In Medium Dose For OCU410—A Modifier Gene Therapy—In Phase 1/2 Armada Study For Geographic Atrophy
05/04/2024 12:12
April 5 (Reuters) - Ocugen Inc OCGN.O :
* OCUGEN ANNOUNCES POSITIVE DATA AND SAFETY MONITORING BOARD
REVIEW AND INITIATION OF ENROLLMENT IN MEDIUM DOSE FOR OCU410—A
MODIFIER GENE THERAPY—IN PHASE 1/2 ARMADA STUDY FOR GEOGRAPHIC
ATROPHY
* OCUGEN INC - DSMB APPROVAL TO PROCEED WITH MEDIUM DOSE
COHORT
DOSING
* OCUGEN INC: ESTABLISHED LOW DOSE AS SAFE AND TOLERABLE
DOSE IN
CURRENT OCU410 CLINICAL TRIAL
Source text for Eikon: ID:nGNX51JY6G
Further company coverage: OCGN.O